AGCC vs BEAM vs STZ vs EDIT

For growth investors, Agencia Comercial Spirits Ltd (AGCC) is the stronger pick with 186.

0% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Analysts rate Beam Therapeutics Inc. (BEAM) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Agencia Comercial Spirits Ltd (AGCC) delivered a total return of +218.

3%, compared to -90. 8% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: AGCC returned +218. 3% versus EDIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Constellation Brands, Inc.

(STZ) is the lower-risk stock at 0. 28β versus Editas Medicine, Inc. 's 2. 45β — meaning EDIT is approximately 790% more volatile than STZ relative to the S&P 500. On balance sheet safety, Agencia Comercial Spirits Ltd (AGCC) carries a lower debt/equity ratio of 7% versus 170% for Constellation Brands, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agencia Comercial Spirits Ltd (AGCC) is pulling ahead at 186.

0% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -104. 8% for Constellation Brands, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agencia Comercial Spirits Ltd (AGCC) is the more profitable company, earning 30.

7% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 30. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGCC leads at 40. 0% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for EDIT: 70.

6% to $5. 00.

In this comparison, STZ (2.

8% yield) pays a dividend. AGCC, BEAM, EDIT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Constellation Brands, Inc.

(STZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 2. 8% yield). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STZ: +7. 3%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AGCC (Consumer Defensive) and BEAM (Healthcare) and STZ (Consumer Defensive) and EDIT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AGCC is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; STZ is a mid-cap quality compounder stock; EDIT is a small-cap quality compounder stock. STZ pays a dividend while AGCC, BEAM, EDIT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.